Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00313248 · ClinicalTrials.gov registry record · Phase 2

Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

A Phase 2 study of Breast Neoplasm, sponsored by Bayer.

Completed
Registry status
Phase 2
Development phase
65
Enrollment target
20
Study locations

NCT00313248 is a Phase 2 study of Breast Neoplasm that has completed, run by Bayer. The registered enrollment target is 65 participants, below the 160-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00313248, a Phase 2 study of Breast Neoplasm, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 2
Development phase
65 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) in patients with metastatic breast cancer helps to decrease or stop tumor growth.

Conditions Studied

Breast Neoplasm

Interventions

  • DRUG Sagopilone (ZK 219477)

Study Locations (20)

California

  • - Bakersfield
  • - Palm Springs

New York

  • - New York
  • - Syracuse

Texas

  • - Houston
  • - San Antonio

Alabama

  • - Birmingham

Alaska

  • - Anchorage

Arizona

  • - Tucson

Arkansas

  • - Hot Springs

Colorado

  • - Aurora

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2006-04
Est. Completion 2008-11
Phase Phase 2

Sponsor

Bayer

591 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00313248

The ClinicalTrials.gov registry entry for NCT00313248 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 160-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (59% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Sagopilone (ZK 219477) is the first listed.

NCT00313248 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT00313248 about?

NCT00313248 is a clinical study titled "Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer". The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) in patients with metastatic breast cancer helps to decrease or stop tumor growth.

What is the current status of trial NCT00313248?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2006-04. Estimated completion is 2008-11.

What conditions does trial NCT00313248 study?

This clinical trial studies the following conditions: Breast Neoplasm.

What interventions are being tested in trial NCT00313248?

The interventions under investigation include: Sagopilone (ZK 219477) (DRUG).

Who is sponsoring clinical trial NCT00313248?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00313248 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Neoplasm

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.